BRPI0519031A2 - compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio - Google Patents

compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio

Info

Publication number
BRPI0519031A2
BRPI0519031A2 BRPI0519031-2A BRPI0519031A BRPI0519031A2 BR PI0519031 A2 BRPI0519031 A2 BR PI0519031A2 BR PI0519031 A BRPI0519031 A BR PI0519031A BR PI0519031 A2 BRPI0519031 A2 BR PI0519031A2
Authority
BR
Brazil
Prior art keywords
compounds
compositions
modulators
calcium channel
receptor activity
Prior art date
Application number
BRPI0519031-2A
Other languages
English (en)
Inventor
Pierre-Yves Michellys
Wei Pei
John Wityak
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0519031A2 publication Critical patent/BRPI0519031A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

COMPOSTOS E COMPOSIÇÕES COMO MODULADORES DE ATIVIDADES DE RECEPTORES ESTEROIDAIS E DE CANAL DE CÁLCIO. A invenção fornece compostos, composições farmacêuticas que compreendem tais compostos, e métodos de empregar tais compostos para tratar ou prevenir doenças ou distúrbios associados com a ativação de re- ceptores nucleares de hormônio esteróide.
BRPI0519031-2A 2004-12-13 2005-12-13 compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio BRPI0519031A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63576004P 2004-12-13 2004-12-13
US65224805P 2005-02-11 2005-02-11
PCT/US2005/045449 WO2006066011A2 (en) 2004-12-13 2005-12-13 Compounds and compositions as modulators of steroidal receptors and calcium channel activities

Publications (1)

Publication Number Publication Date
BRPI0519031A2 true BRPI0519031A2 (pt) 2008-12-23

Family

ID=36588558

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519031-2A BRPI0519031A2 (pt) 2004-12-13 2005-12-13 compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio

Country Status (10)

Country Link
US (1) US20090298872A1 (pt)
EP (1) EP1828135A4 (pt)
JP (1) JP2008523108A (pt)
KR (1) KR20070087602A (pt)
AU (1) AU2005316511B2 (pt)
BR (1) BRPI0519031A2 (pt)
CA (1) CA2589777A1 (pt)
MX (1) MX2007007102A (pt)
RU (1) RU2007126551A (pt)
WO (1) WO2006066011A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005034264A1 (de) * 2005-07-22 2007-02-01 Bayer Healthcare Ag 4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung
DE102005034267A1 (de) * 2005-07-22 2007-01-25 Bayer Healthcare Ag 4-Chromenonyl-1,4-dihydropyridine und ihre Verwendung
DE102006026585A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102006044696A1 (de) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
ES2396160T3 (es) * 2006-12-14 2013-02-19 Bayer Intellectual Property Gmbh Derivados de DIHIDROPIRIDINA que utiliza como inhibidores de la proteina quinasa
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
US20100261765A1 (en) * 2007-12-14 2010-10-14 Brandish Philip E Mineralocorticoid receptor modulators
US8551989B2 (en) 2008-06-09 2013-10-08 Bayer Intellectual Property Gmbh Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof
US8759341B2 (en) 2009-02-18 2014-06-24 Bayer Intellectual Property Gmbh Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
JP5674211B2 (ja) 2009-07-10 2015-02-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法
UY32922A (es) 2009-10-06 2011-04-29 Bayer Schering Pharma Ag Derivados de 3, 5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos
US20120270905A1 (en) 2009-10-06 2012-10-25 Bayer Pharma Aktiengesellschaft Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof
CA2777907C (en) 2009-11-11 2017-08-29 Bayer Pharma Aktiengesellschaft Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
CA2780977C (en) * 2009-11-18 2018-01-16 Martin Michels Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof
US20150296779A1 (en) * 2012-11-28 2015-10-22 Stichting Dienst Landbouwkundig Onderzoek Substituted dihydropyridines for somatic embryogenesis in plants
EP3480201A1 (en) * 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
RU2755349C1 (ru) * 2021-02-16 2021-09-15 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Применение бензил 6-({ 2-[(3,4-диметилфенил)амино]-2-оксоэтил} тио)-2-метил-4-(4-хлорфенил)-5-циано-1,4-дигидропиридин-3-карбоксилата в качестве гепатопротекторного средства

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
WO2000078720A1 (en) * 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyridine derivative
BR0315103A (pt) * 2002-10-07 2005-08-16 Artesian Therapeutics Inc Compostos de diidropiridina tendo capacidade simultânea de bloquear os canais de cálcio do tipo l e inibir a atividade da fosfodiesterase do tipo 3

Also Published As

Publication number Publication date
EP1828135A2 (en) 2007-09-05
MX2007007102A (es) 2007-08-08
RU2007126551A (ru) 2009-01-20
WO2006066011A2 (en) 2006-06-22
WO2006066011A3 (en) 2006-08-03
JP2008523108A (ja) 2008-07-03
KR20070087602A (ko) 2007-08-28
AU2005316511B2 (en) 2009-12-03
CA2589777A1 (en) 2006-06-22
AU2005316511A1 (en) 2006-06-22
EP1828135A4 (en) 2009-08-12
US20090298872A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
BRPI0512674A (pt) compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
BRPI0519031A2 (pt) compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio
BRPI0511477A (pt) compostos e composições como moduladores de ppar
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
MX2020011562A (es) Agonistas del receptor de la hormona tiroidea y usos de los mismos.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
PA8576901A1 (es) Moduladores del receptor de glucocorticoides
ECSP088402A (es) Compuestos y composiciones que contienen diarilamina, y su utilización como moduladores de los receptores c-kit
ZA200705115B (en) Indazole-carboxamide compounds
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
EA200900202A1 (ru) Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
EP4603142A3 (en) Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
BRPI0511099A (pt) compostos e composições como moduladores de ppar
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
WO2007092065A3 (en) Compounds and compositions as lxr modulators
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
BRPI0511527A (pt) compostos e composições como moduladores de ppar
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
DE602005016446D1 (de) 5-HT4-Rezeptoragonistenverbindungen

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE.